儿童遗传性足细胞病钙调神经磷酸酶抑制剂反应持续性与长期肾脏存活的多国研究
该多国回顾性队列纳入34个儿童肾脏中心136例0-18岁遗传性足细胞病患者,CNI治疗至少3个月。中位随访42.1个月,6个月和末次随访至少部分缓解率分别为28%和22%。持续缓解者随访期间无肾衰竭发生,非持续缓解者肾衰竭风险较无缓解者低92%。
要点
- 儿童遗传性足细胞病CNI治疗6个月至少部分缓解率为28%。
- 持续缓解者随访42个月期间无肾衰竭发生。
- 非持续缓解者肾衰竭风险较无缓解者低92%。
核心结论
- 部分遗传性足细胞病患儿对CNI产生持续缓解且均未发生肾衰竭。
- 非持续缓解患儿肾脏存活仍优于无缓解者,支持临床缓解者继续治疗。
研究设计与样本
- 多国回顾性队列研究,纳入34个儿童肾脏中心0-18岁遗传性足细胞病患者136例。
- CNI治疗至少3个月,中位随访42.1个月(CNI起始至末次随访或肾脏替代治疗起始)。
- 缓解状态依据国际儿童肾脏病协会临床实践建议定义。
主要发现
- CNI起始后6个月和末次随访至少部分缓解率分别为28%和22%。
- 6个月至少部分缓解者CNI后多个时间点尿蛋白/肌酐比值显著低于无缓解组。
- 观察期内无缓解、非持续缓解和持续缓解分别占71%、11%和18%。
- 持续缓解和非持续缓解均与更优肾脏存活显著相关。
- 持续缓解者随访42(四分位距19-62)个月无肾衰竭发生;非持续缓解者肾衰竭风险较无缓解者低92%。
临床怎么用
- 遗传性足细胞病患儿可考虑CNI试验性治疗。
- 显示临床缓解者建议继续CNI治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: While calcineurin inhibitors (CNIs) reduce proteinuria in a subgroup of children with genetic podocytopathies, previous reports suggest that the response is short-lived and of no benefit to long-term outcomes. Here, we assess CNI response sustainability and the association between different patterns of response preservation and kidney survival. METHODS: We performed a retrospective cohort study of patients aged 0-18 years with genetic podocytopathies treated with CNIs for at least three months from 34 pediatric nephrology centers worldwide. Response status was defined in accordance with International Pediatric Nephrology Association Clinical Practice Recommendations. RESULTS: We analyzed 136 patients with genetic podocytopathies over a median follow-up period of 42.1 months (between CNI initiation and last follow-up or commencement of kidney replacement therapy, whichever occurred first). At least partial response was attained in 28% and 22% of patients at six months post-CNI initiation and last follow-up, respectively. Compared to no response group, patients with at least partial response at six months had significantly lower urine protein-to-creatinine ratios across various time points post-CNIs. 71%, 11% and 18% exhibited no response, non-sustained and sustained response, respectively, throughout the observation period. Both sustained and non-sustained responses were significantly associated with superior kidney survival compared to no response. Importantly, no patients with sustained response developed kidney failure over a follow-up period of 42 (interquartile range 19-62) months. Patients with non-sustained response had a 92% lower risk of kidney failure compared to non-responders. CONCLUSIONS: A subset of children with genetic podocytopathies experienced a sustained response to CNIs, and none developed kidney failure. Children with non-sustained response still demonstrated superior kidney survival compared to non-responders. Our findings may support a trial of CNIs in genetic podocytopathies, and continuing therapy among those showing clinical response.
引用
- Malakasioti G, Iancu D, Au CT, et al. A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies. Kidney Int. 2026. PMID: 42508611. doi:10.1016/j.kint.2026.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。